Cell Signaling Technology

Product Pathways - Apoptosis

SignalSilence® XIAP siRNA II #6550

Applications Reactivity
Transfection H

Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® XIAP siRNA II (+), using XIAP Antibody #2042 and β-Actin Antibody #4967. The XIAP antibody confirms silencing of XIAP expression, while the β-Actin Antibody is used to control for loading and specificity of XIAP siRNA.

Description

SignalSilence® XIAP siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit XIAP expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce protein expression by western analysis.

Directions for Use

CST recommends transfection with 100 nM XIAP siRNA II. Decreased XIAP expression was seen 48 to 72 hours post-transfection. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

Background

The inhibitor of apoptosis protein (IAP) family consists of an evolutionarily conserved group of apoptosis inhibitors containing a conserved 70 amino acid BIR (baculovirus inhibitor repeat) domain (1,2). Human members of this family include c-IAP1, c-IAP2, XIAP, survivin, livin, and NAIP. Overexpression of IAP family members, particularly survivin and livin, in cancer cell lines and primary tumors suggests an important role for these proteins in cancer progression (3-5). In general, the IAP proteins function through direct interactions to inhibit the activity of several caspases, including caspase-3, caspase-7, and caspase-9 (5,6). In addition, binding of IAP family members to the mitochondrial protein Smac blocks their interaction with caspase-9, thereby allowing the processing and activation of the caspase (2).

  1. Deveraux, Q.L. and Reed, J.C. (1999) Genes Dev 13, 239-52.
  2. Deveraux, Q.L. et al. (1998) EMBO J 17, 2215-23.
  3. Altieri, D.C. et al. (1999) Lab Invest 79, 1327-33.
  4. Tamm, I. et al. (2000) Clin Cancer Res 6, 1796-803.
  5. Kasof, G.M. and Gomes, B.C. (2001) J Biol Chem 276, 3238-46.
  6. Deveraux, Q.L. et al. (1997) Nature 388, 300-4.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products